Source: Citybizlist

Spero Therapeutics: Spero Therapeutics Appoints Esther Rajavelu as CEO

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) - Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing... Read MoreThe post Spero Therapeutics Appoints Esther Rajavelu as CEO appeared first on citybiz.

Read full article »
Spero Therapeutics's Competitors | Spero Therapeutics's News | Spero Therapeutics's Financials
Stay up-to-date with the latest news on Spero Therapeutics
Annual Revenue
$25-100M
Employees
25-100
Sath Shukla's photo - President & CEO of Spero Therapeutics

President & CEO

Sath Shukla

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Spero Therapeutics